Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform.

Biotechnology

Immunomic Therapeutics

Eric Winzer

Teri Heiland

Eric Winzer & Board Member

Frances Harrison

Scott Rodgers

Cara Sholter

The Directors team at Immunomic Therapeutics, Inc. provides strategic leadership and governance, ensuring the company advances its clinical-stage biotechnology innovations. They oversee various functions, including research, development, regulatory affairs, and finance, to drive the success of the UNITE nucleic acid immunotherapy platform.

Directors

Scientific Team

Leadership Team

Directors

About

Team members

Other teams at Immunomic Therapeutics

Scientific Team

Leadership Team